Citations

Clear

941 citation(s) found for "Tan, E".

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
McKay, Rana R. , Ballman, Karla V. , Atherton, Pamela J. , Ajmera, Archana , Baghdadi, Tareq Al, Baumann, Brian C. , Beltran, Himisha , Berg, Stephanie , Chen, Ronald C. , Choudhury, Atish D. , Jacene, Heather A. , Kilari, Deepak , Kwok, Young , Swami, Umang , Tan, Alan , Yang, Yuanquan , Zhang, Tian , Galsky, Matthew D. , George, Daniel J. , Baghdadi, Tareq Al , Cole, Suzanne , Jacene, Heather A , Lang, Joshua M , Kilari, Deepak , Kwok, Young , McGregor, Bradley , Morris, Michael J , Parikh, Mamta , Swami, Umang , Tan, Alan , Yang, Yuanquan A , Zhang, Tian , Galsky, Matthew D , Rosenberg, Jonathan E , George, Daniel J , Choueiri, Toni K , Baumann, Brian C , Choudhury, Atish D , Chen, Ronald , Ballman, Karla , Berg, Stephanie A , Cole, Suzanne , Lang, Joshua M. , McGregor, Bradley A. , Morris, Michael J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | July 27, 2026 | Volume: 44 | Issue: 24 | Pages: 2341-2352

10.1200/jco-26-01135 | PMID 42507969 Get It

PURPOSE Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223 ) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS This phase II trial enrolled patients with mRCC of any histology with ≥1 BM. Patients were randomly assigned 1:1 to cabozantinib ± radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, opioid use, and International mRCC Database Consortium (IMDC) risk. The primary end point was SSE-free survival (SSE-FS). Secondary end points included safety, objective response rate (ORR), progression-free survival, and overall survival (OS). A target of 124 evaluable patients was planned, with a prespecified interim futility analysis at 50% of expected SSE-FS events; the trial would stop if the stratified hazard ratio (sHR) > 1.0. RESULTS The prespecified interim futility analysis was conducted after 90 patients were enrolled and crossed the futility boundary, leading to closure at 98 patients. The final analysis included all 98 patients. Median age was 63 years, 82.7% had clear cell histology, and 79.6% were using an OTT. IMDC risk was favorable (18.4%), intermediate (67.3%), and poor (14.3%). Median follow-up was 13.1 months. Median SSE-FS for cabozantinib with radium-223 versus cabozantinib was 16.7 versus 17.6 months (sHR, 1.46 [90% CI, 0.86 to 2.51]). Median OS was 28.3 versus 19.7 months (sHR, 1.40 [95% CI, 0.70 to 2.79]). ORR was 19.4% versus 25.0% ( P = .78). Grade ≥3 adverse events were similar across arms (69.6% v 75.5%). CONCLUSION Radium-223 did not improve SSE-FS when added to cabozantinib. The combination demonstrated a manageable safety profile.
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Sievers, Quinlan , Lu, Hao , Cool, Allison , Gajewski, Stefan , Kong, Tim , Noviski, Mark , Whelan, Sarah , Wang, Yuhan , Navarrete, Lizbeth Mendoza, Mi, Xiaoli , Mukerji, Ratul , Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Tan, Y. , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya‐Wen , Elechko, Jennifer, Phelps, Christopher B., Sekeres, Samantha, Bravo, Eduardo , Alencar, Alvaro J. , Islam, Prioty , Mato, Anthony R. , Noviski, Mark A , Wang, Yuhan , Mendoza Navarrete, Lizbeth , Ficici, Emel , Mukerji, Ratul , Iuliano, James N , Ye, Jordan , Sanchez Garcia De Los Rios, Mateo , Bousquet, Hugo , Tan, May , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya-Wen , Elechko, Jennifer , Maron, Maxim I , Phelps, Christopher B , Rahman, Jahan , Notti, Ryan Q , Sekeres, Samantha , Lamkin, Erica N , Bravo, Eduardo , Alencar, Alvaro J , Ewalt, Mark D , Islam, Prioty , Mato, Anthony , Roeker, Lindsey , Bhatt, Shruti , Taylor, Justin , Thompson, Meghan C , Hansen, Gwenn M , Abdel-Wahab, Omar , Lamkin, Erica , Ewalt, Mark D. , Roeker, Lindsey E. , Abdel‐Wahab, Omar

Mayo Clinic

Cancer Discovery | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2159-8290.cd-26-0251 | PMID 42484277 Get It

Abstract Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. Here we sequenced serial CLL samples from patients enrolled in the phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTK A428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTK A428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTK A428D exhibited a competitive disadvantage. A crystal structure of BTK A428D revealed that the mutant aspartate clashes with the adenine ring of ATP and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTK A428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies.
Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies
Adams, Daniel , Hurson, Amber N. , Ahearn, Thomas U, Andrulis, Irene L, Antoniou, Antonis C, Auvinen, Päivi, Bane, Anita, González, Amy Berrington de , Bodelon, Clara, Bolla, Manjeet K. , Borrero, Maria , Brenner, Hermann, Brock, Ian W., Camp, Nicola J. , Cessna, Melissa H., Chanock, Stephen J, Chenevix-Trench, G, Copson, ER, Fh, Couch, Devilee, P, Easton, Douglas F, Eccles, Diana, Figueroa, Jonine D, Glendon, Gord, Hamann, U, Hartman, Mikael, Heemskerk-Gerritsen, Bernadette A M, Hodge, James M, Holleczek, Bernd, Hollestelle, A M, Mj, Hooning, Investigators, kConFab, Amor, David, Andrews, Lesley , Antill, Y , Rl, Balleine, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Bodek, Simon, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Caldon, Liz, Campbell, Ian, Chakrabarti, Anannya , Chauhan, Deepa, Chauhan, Manisha, Christian, Alice, Cohen, Paul, Colley, Alison, Cui, James, Courtney, Eliza, Cummings, Margaret, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Duijf, Pascal, Edwards, Stacey, Farshid, Gelareh , Fellows, AM, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet , Friedlander, Michael, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Harraka, Philip, Hayward, Nick, Hoskins, Cass , Hunt, Clare, James, Paul, Jenkins, Mark, Kidd, Alexa, Koehler, Jessica, Kollias, J, Lakhani, Sunil, Lawrence, Mitchell, Lee, Jason , Li, Shuai, Lindeman, Geoff, Lippey, Jocelyn, Lipton, Lara, Loi, Sherene, Mann, Graham, Marsh, Deborah, McLachlan, Sue Anne, Reed, Amy McCart, Milne, Roger, Nightingale, Sophie , O’Connell, Shona, O’Sullivan, Sarah, Reilly, Robert O', Ortega, David Gallego, Pachter, Nick, Pang, Jia-Min, Pathak, Gargi, Patterson, Briony, Phillips, Kelly, Pieper, Ellen, Ramus, Susan, Rickard, Edwina, Ragunathan, Abi, Robinson, Bridget, Skandarajah, Anita, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Scott, Rodney, Scott, Clare, Sexton, Adrienne, Shaw, Joanne, Shelling, Andrew, Srinivasa, Shweta , Simpson, Peter, Mc, Southey, Spurdle, Amanda, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, A H, Tucker, Kathy , Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, I, Young, Mary Ann, Zaheed, Milita , Investigators, S On Behalf Of The Chlovis Study, Tan, Veronique Kiak Mien , Lim, Geok Hoon, Tan, Ern Yu , Tan, Su-Ming, Iau, Philip Tsau Choong , Jakubowska, A, Jones, Michael E. , Jones, Louise , Jones, Brandt, Jung, Audrey, Kaaks, Rudolf, Keeman, Renske , Lawrence, Scott, Li, J M, Lubiński, J, Mannermaa, Arto, Manoochehri, Mehdi, Martens, John W M, Mesker, Wilma E, Muhammad, Noor , Obi, Nadia, Olson, Janet E, Patel, Alpa V, Prajzendanc, Karolina , Ruddy, Kathryn J, Safizadeh, Fatemeh , Schöttker, Ben, Tengström, Maria , Le, Teras, Timmermans, M, Tollenaar, RA, Vachon, Celine M, Wang, Q, Yang, Xiaohong R, Zamora, M Pilar, Chang-Claude, Jenny, Schmidt, M K, Pharoah, Paul D P, Abubakar, Mustapha, Eccles, Diana , Ahearn, Thomas U. , Eccles, Diana , Jones, Michael E , Jones, J. Louise , Berrington de Gonzalez, Amy , Antoniou, Antonis C. , Bane, Anita, Behrens, Sabine , Białkowska, Katarzyna , Bodelón, Clara , Brenner, Hermann , Broeks, Annegien , Chanock, Stephen Jacob , Chenevix‐Trench, Georgia , Copson, Ellen , Couch, Fergus J, Cox, Angela , Cross, Simon S. , Devilee, Peter , Dunning, Alison M. , Easton, Douglas F. , Figueroa, Jonine D. , Glendon, Gord, González‐Neira, Anna , Hartikainen, Jaana M. , Hartman, Mikael , Heemskerk‐Gerritsen, Bernadette A. M. , Ho, Peh Joo , Hodge, James M. , Holleczek, Bernd , Hollestelle, Antoinette , Hooning, Maartje J. , Investigators, kConFab, Balleine, Rosemary L. , Bennett, Ian, Bogwitz, Michael R. , Bodek, Simon , Botes, Leon P., Buckley, Michael , Cohen, Paul A. , Crook, Ashley , Courtney, Eliza , Dawson, Sarah‐Jane , DeFazio, Anna , Delatycki, Martin B. , Duijf, Pascal H. G. , Fellows, Andrew, Fenton, Georgina L. , Flanagan, James M. , Forrest, Laura Elenor , Friedländer, Michael , Harraka, Philip A. , Kidd, Alexa, Kollias, James, Lakhani, Sunil R. , Lawrence, Mitchell, Lindeman, Geoffrey J. , Lippey, Jocelyn , Loi, Sherene , Reed, Amy E. McCart , Milne, Roger L , Gallego‐Ortega, David , Pathak, Gargi, Pearn, Amy , Robinson, Bridget A. , Skandarajah, Anita Rohini , Salisbury, Elizabeth, Saunders, Christobel , Saunus, Jodi M. , Savas, Peter Stephen , Sexton, Adrienne , Shelling, Andrew Neil , Simpson, Peter, Spurdle, Amanda B. , Visvader, Jane E. , Williams, Rachael, Tan, Bien‐Keem , Lim, Geok Hoon , Kaaks, Rudolf , Lawrence, Scott M. , Lissowska, Jolanta , Mannermaa, Arto , Manoochehri, Mehdi, Mesker, Wilma E. , Mulligan, Anna Marie , Obi, Nadia , Olson, Janet E. , Osório, Ana , Ottewell, Penelope Dawn , Patel, Alpa V , Pita, Guillermo , Rashid, Muhammad Usman , Ruddy, Kathryn J. , Schöttker, Ben , Seibold, Petra , Tapper, William , Teras, Lauren R , Timmermans, Mieke, Vachon, Celine M. , Wesseling, Jelle , Yadav, Siddhartha , Chang‐Claude, Jenny , Schmidt, Marjanka K. , Abubakar, Mustapha , García‐Closas, Montserrat

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag244 | PMID 42498670 Get It

Abstract Background Breast cancer is etiologically heterogeneous, but which risk factors differ in their associations across tumor subtypes remains unclear. We conducted a large, pooled analysis to evaluate independent, dose-response associations between breast cancer risk factors and quantitative tumor features. Methods Analyses of 15,731 invasive breast cancers from 24 studies evaluated associations (p-trend) between reproductive and hormonal factors, body mass index (BMI), alcohol, smoking, and family history in relation to quantitative immunohistochemistry measures on tissue microarrays (ER, PR, HER2, KI67, TP53) and tumor grade. Analyses in a subset of 10 population-based studies estimated subtype-specific odds ratios (ORs) comparing cases to controls. A Bayesian False Discovery Probability (BFDP) <0.2 was used to identify associations with strong statistical evidence. Results Nulliparity and later age at menopause were associated with higher ER-positivity (p-trend=0.021 and 0.001, respectively), with corresponding OR[ER+] (95% CI) = 1.49 (1.16-1.90) for nulliparous vs. parous and 1.07 (1.03-1.11) per 5 years. Current combined menopausal hormone therapy (MHT) use was associated with lower grade (p-trend<0.001), with OR [grade1] = 3.37 (2.69-4.21) for current vs. never users. Higher BMI was associated with lower ER-positivity and higher grade in premenopausal women (p-trend<0.001 and <0.001), with OR[ER+] = 0.80 (0.74-0.87) and OR[grade1] = 0.75 (0.63-0.88) per 5 units, and with higher PR-positivity and higher grade in postmenopausal women (p-trend<0.001 and <0.001), with OR[PR+] = 1.08 (1.03-1.14) and OR[grade 3] = 1.10 (1.04-1.17) per 5 units. Conclusion This pooled analysis of 15,731 cases showed that nulliparity, age at menopause, MHT, and BMI have independent, dose-response associations with ER, PR, and grade, clarifying patterns of etiologic heterogeneity. Associations with HER2, KI67 and TP53, or other risk factors did not meet our threshold for strong evidence.
Fluorescence In Situ Hybridization Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Testing Results From the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee
Peterson, Jess F., Tang, Guilin, Mixon, Christopher, Zepeda-Mendoza, Cinthya J., Sukov, William R., Zou, Ying S., Nusapan, Rangsinee, Tan, Julian, Dvorak, James, Velagaleti, Gopalrao V., Fang, Min, Levy, Brynn, Miron, Patricia M., Cao, Yang, Astbury, Caroline, Gardner, Juli-Anne, Peterson, Jess F. , Tang, Guilin , Mixon, Christopher , Zepeda‐Mendoza, Cinthya , Sukov, William R. , Zou, Ying S , Nusapan, Rangsinee , Dvorak, James, Velagaleti, Gopalrao V.N. , Fang, Min , Miron, Patricia Minehart , Astbury, Caroline , Gardner, Juli-Anne

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 16, 2026 | Volume: 150 | Issue: 12 | Pages: 942-947

10.5858/arpa.2026-0083-cp | PMID 42457191 Get It

Context.— One objective of the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee is to ensure the accurate detection and clinical interpretation of abnormalities observed by fluorescence in situ hybridization (FISH) analysis when evaluating hematologic neoplasms. Objective.— To report a 20-year performance summary (2005–2024) of FISH challenges focusing on hematologic neoplasms. Design.— A retrospective review was performed from 2005 through 2024 to identify FISH challenges specifically addressing hematologic neoplasms. The overall performance of participants was evaluated to identify potential recurring errors of clinical relevance. Results.— A total of 124 hematologic neoplasm FISH challenges from 2005 to 2024 were provided to participating laboratories, including 45 paper challenges (results and/or images were provided for interpretation purposes), 43 liquid challenges (bone marrow aspirate or peripheral blood), and 36 formalin-fixed, paraffin-embedded (FFPE) tissue challenges. Of the 124 challenges, 120 (97%) exceeded the required 80% consensus for grading purposes. Of the 4 failed challenges (3%), 2 (1 liquid, 1 paper) involved the interpretation of atypical FISH signal patterns; 1 (paper) involved the interpretation of FISH signal patterns correlating involvement by myeloid versus lymphoid interphase nuclei; and 1 (liquid) likely involved a specimen processing or handling error that resulted in discordant participant responses. All 36 FFPE tissue challenges exceeded the 80% consensus for grading purposes. Conclusions.— This 20-year retrospective review demonstrates that clinical cytogenomic laboratories have been and continue to be highly proficient in the detection and interpretation of FISH abnormalities associated with hematologic neoplasms.
An Unexpected Encounter: When a Novel Device Algorithm Meets a Novel Ablation System
Makkar, Nayani , Mulpuru, Siva K., DeSimone, Christopher V. , Hayes, David L. , Tan, Nicholas Y. , Ezzeddine, Fatima , DeSimone, Christopher V , Tan, Nicholas , Mulpuru, Siva K. , Ezzeddine, Fatima M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 8, 2026 | Volume: 37 | Issue: 8 | Pages: 1883-1885

10.1111/jce.70449 | PMID 42418732 Get It

TAF7 accumulates in the cytoplasm during cellular transformation and engages STAT3, WASH, and CCT
Cheng, Dan , McManus, Elizabeth , Young, Ryan M. , Oellerich, Thomas , Häupl, Björn , Billadeau, Daniel D. , Tan, Hua , Elnitski, Laura, Singer, Dinah S , McManus, Elizabeth

Mayo Clinic

Frontiers in Cell and Developmental Biology | July 8, 2026 | Volume: 14 | Issue: No issue available | Pages: No page available

10.3389/fcell.2026.1855716 | PMID 42488556 Get It

TAF7, a core subunit of the general transcription factor TFIID, regulates transcription and additionally functions as an RNA chaperone that directs nascent nuclear RNAs to cytoplasmic polysomes, thereby influencing protein synthesis. Here, we identify a set of novel cytoplasmic interactors and a previously unappreciated cytoplasmic role for TAF7 in oncogenesis. BioID-mediated proximity labeling identified STAT3 and the CCT and WASH complexes as prominent cytoplasmic interactors of TAF7. These interactions were validated by co-immunoprecipitation and proximity ligation assays. We further showed that cytoplasmic TAF7 levels increased during oncogenesis in proportion to cancer cell pathogenicity. Notably, TAF7 engagement with STAT3, CCT and WASH complexes is markedly enhanced during cellular transformation, consistent with their functions in cancer progression. Together, these findings reveal a cytoplasmic TAF7 interactome and implicate elevated cytoplasmic TAF7 as associated with oncogenesis.
Association of a Polygenic Risk Score with Diagnosis and Outcomes in Idiopathic Pulmonary Fibrosis
Kalra, S. , Grilli, Christopher, Coombes, Brandon J. , Armasu, Sebastian M. , Upjohn, D, Egan, Jan B. , Chen, Qingwen , Tern, Courtney , Zhang, Chengyue, Rose, Jonathan A. , Putman, Rachel, McDermott, Greg, Hsieh, Yuli Lily , Bublitz, Michele L., Carmona, Eva M. , Klee, Eric W, Lazaridis, K, Peljto, Anna L. , Schwartz, D A, Silverman, Edwin K. , Olson, Janet, Walker, T, Zamora, Ana C., Zein, Joe , Ortega, V E, Cohort, Tapestry, McDermott, Gregory C , Kalra, Sean S , Grilli, Christopher B , Armasu, Sebastian , Upjohn, David P , Hsieh, Yuli L , Lasky-Su, Jessica , Silverman, Edwin K , Allen, Richard J , Walker, T'Nita, Wain, Louise V , Zamora, Ana, Zein, Joe G, Hunninghake, Gary M , Moll, Matthew , Cho, Michael H , Carmona, Eva M , McDermott, Gregory , Coombes, Brandon J , Putman, Rachel K. , Kn, Lazaridis, Lasky‐Su, Jessica , Dudbridge, Frank , Allen, Richard J. , Olson, JA, Hunninghake, Gary M. , Ali, Ahmad Hafiz , Sekulić, Aleksandar , Athreya, Arjun P. , Clermont, Blake J, N, Brittany, Burnap, Graddy, Courtney B., Cahn, Elliot, Klee, Eric W. , Sicotte, Hugues , Ekpoh, Idara U., Frank, Jacob A., Bruflat, Jamie K., Kemppainen, Jennifer L., Samadder, Jewel, Presutti, John J, Leitzke, Jon W, Lazaridis, Konstantinos N. , Tree, Kristine M, Jones, Leila A, Bandel, Lorelei A. , Karow, Mary E., Peterson, Melanie M., Bublitz, Michelle L. , Morales-Rosado, Joel, Erwin, Nate P., Larson, Nicholas B. , Olson, Rory, Vierkant, Robert A., Pignolo, Robert J. , Safgren, Stephanie, Bagaria, Sanjay P. , Tian, Shulan , Kaggal, Suneetha, Walker, T'Nita S., Wilson, Tammy A., McAllister, Tammy M., Tan-Arroyo, Jennifer, Luehrs, Tony, Ortega, Victor E. , Chen, Wenan , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag271 | PMID 42391602 Get It

Abstract Rationale Idiopathic Pulmonary Fibrosis (IPF) is characterized by chronic progressive pulmonary fibrosis and high mortality. Genetic markers, summarized into a polygenic risk score (PRS), associate with IPF in well-phenotyped research cohorts. Objectives To evaluate the performance of the PRS using real-world data from routinely captured electronic healthcare records. Methods We conducted an observational study evaluating the association of a PRS for IPF with electronic healthcare record diagnosis of IPF as well as lung transplant-free survival in four independent cohorts; the Mass General Brigham Biobank (MGBB), Mayo Clinic Biobank (MCBB), Mayo Clinic Tapestry Cohort (Tapestry), and U.K. Biobank (UKBB). We used multivariable logistic regression and multivariable Cox proportional hazards models adjusting for age, gender, and principal components of ancestry. The cohorts then underwent fixed and random effects meta-analysis. Measurements and Main Results Of 37,709; 44,195; 43,202; and 447,422 participants from MGBB, MCBB, Tapestry and UKBB respectively, 1,015 (2.7%) 2,879 (6.5%), 1,310 (3.0%), and 2,742 (0.6%) participants had an IPF diagnosis. Meta-analysis demonstrated a high-risk PRS associated with IPF diagnosis, OR 2.88 (95%CI 2.41-3.44) compared to all other individuals. A high-risk PRS also associated with the composite endpoint of mortality or lung transplant among those with an IPF diagnosis, HR 1.23(95%CI 1.11-1.35) compared to all other individuals. Conclusions A PRS can identify those at risk for an IPF diagnosis and mortality in biobank-scale data, which may have implications for clinical decisions. Further work is necessary to evaluate the utility of adding genetics in clinical settings.
A Second Report of a Missense Variant in AMMECR1 Causing Midface Hypoplasia, Hearing Impairment, Elliptocytosis, and Nephrocalcinosis: Case Report and Lit
Tan, Jia W., Wilke, Matheus Vernet Machado Bressan , Panwar, Deepak , Kahn, Eva S., Figueiral, Marta , Xiao, Yao , Sas, David J. , Lanpher, Brendan C. , Vairo, Filippo Pinto e, Klee, Eric W. , Pinto E Vairo, Filippo, Wilke, Matheus V M B , Panwar, Deepak , Dikilitas, Ozan

Mayo Clinic

Clinical Genetics | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/cge.70209 | PMID 42386221 Get It

ABSTRACT Pathogenic variants in AMMECR1 have been associated with a rare multisystem disorder characterized by midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis (MFHIEN). To date, most reported cases involve copy number variants or presumed loss‐of‐function alterations, with only a single prior report describing a missense variant supported by functional studies. Here, we report a patient with a heterozygous de novo AMMECR1 missense variant, NM_015365.3:c.649G>A p.(Val217Met) presenting with clinical features consistent with MFHIEN, including midface hypoplasia, partial hearing impairment, nephrocalcinosis, and elliptocytosis identified on peripheral blood smear. Comparative review of the literature highlights that while previously reported missense variants in AMMECR1 demonstrated altered intranuclear protein distribution and reduced expression in functional assays, clinical evidence supporting pathogenicity of non‐truncating variants remains limited. The phenotypic overlap between our patient and prior report strengthens the association between missense variations and the MFHIEN phenotype. Our findings support the pathogenic relevance of missense variation in AMMECR1 and emphasize the importance of integrating detailed phenotyping, including hematologic evaluation, with genomic data in the diagnosis of rare multisystem disorders. Additional cases and functional studies are needed to clarify genotype–phenotype correlations and underlying disease mechanisms.
Targeting the S100A2–RAGE Pathway Restores AT2 Cell Identity and Mitigates Lung Fibrosis
Zhou, Changli , Bagherpoor, Alireza Jian, Deng, Wei, Tschumperlin, Daniel, Tan, Qi, Wellmerling, Jack H, Wellmerling, Jack , Tschumperlin, Daniel J. , Tan, Qi

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag133 | PMID 42576310 Get It

Abstract Lung fibrosis, including idiopathic pulmonary fibrosis (IPF), represents a spectrum of progressive interstitial lung diseases characterized by disrupted epithelial repair, fibroblast activation, and excess extracellular matrix accumulation. A central feature of fibrotic progression is the loss of alveolar type 2 epithelial (AT2) cell identity and the emergence of aberrant transitional states that fail to support normal regeneration. Based on our re-analysis of multiple publicly available scRNA-seq datasets from the IPF Cell Atlas, S100A2 expression is tightly associated with basal-like reprogramming of AT2 cells and is a top upregulated gene at both mRNA and protein levels in IPF lungs. Furthermore, scRNA-seq data from human lung organoid models reveal that AT2 cells co-cultured with fibroblasts acquire a basal-like phenotype and express high levels of S100A2. Functionally, overexpression of S100A2 in human iPSC-derived lung alveolar epithelial type 2 (iAT2) cells leads to loss of AT2 cellular identity, increased generation of reactive oxygen species, and activation of RAGE signaling pathway. We demonstrate that pharmacologic inhibition of RAGE using Azeliragon preserves AT2 cell populations, associated with reduced oxidative stress in iAT2 cells, and significantly attenuates collagen deposition in bleomycin-induced lung fibrosis models. Collectively, our results indicate that S100A2 is a key driver of epithelial dysfunction in lung fibrosis, promoting loss of AT2 identity, aberrant basal fate acquisition, and persistent epithelial injury. Targeting the unrecognized S100A2–RAGE pathway may offer a new therapeutic strategy to restore epithelial homeostasis in lung fibrosis.
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.